AlloSure is an emerging standard of care for kidney transplant patients, providing a direct measure of organ injury.

Jan 1, 2025 · AlloSure Kidney is an assay designed to detect allograft rejection in kidney transplant recipients.

AlloSure is a donor-derived cell-free DNA (dd-cfDNA) test for noninvasive transplant surveillance, providing a direct measure of organ injury. Cell-free DNA is fragmented DNA originating from …

Explore the Allosure test, a non-invasive method for monitoring kidney transplant health using cell-free DNA. Discover its applications, interpretative techniques, and future in patient care. 🫀🔬

AlloSure is a Clinical-Grade Testing Service for Quantifying dd-cfDNA, a Clinically Validated Biomarker for Antibody-Mediated Rejection

AlloSure, innovation in action AlloSure is clinically and analytically validated, non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury.

Test Description: The AlloSure test measures donor-derived cell-free DNA (dd-cfDNA) in renal transplant recipients. dd-cfDNA refers to fragments of DNA in the recipient’s bloodstream that …

The AlloSure test is intended to assess the probability of allograft rejection in kidney transplant recipients with clinical suspicion of rejection and to inform clinical decision-making about the …

Aug 6, 2025 · "Our findings demonstrate that [AlloSure Plus] can detect a phenotype of rejection that is associated with increased risk of graft loss but is notoriously difficult to identify using …

Mar 11, 2025 · "We are thrilled to introduce two new expanded indications of AlloSure, addressing critical needs in transplant patient care. Until now, children under 15 who received a heart …